TITLE:
Efficacy of Para-Aortic Lymphadenectomy in Ovarian Cancer: A Retrospective Study
AUTHORS:
Hiromi Ugaki, Yosiko Komoto, Reisa Kakubari, Eriko Tanaka, Hisashi Konishi, Toshihiro Kitai, Saori Nakajima, Miho Muraji, Takayuki Enomoto, Masahiko Takemura
KEYWORDS:
Ovarian Cancer; Pelvic Lymphadenectomy; Para-Aortic Lymphadenectomy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.5A,
May
24,
2013
ABSTRACT: Objective: The prognostic impact for ovarian cancer treatment of employing a systematic para-aortic and pelvic lymphadenectomy is still poorly defined. The purpose of this study was to evaluate the therapeutic efficacy of adding a para-aortic lymphadenectomy (PA) to the pelvic lymphadenectomy (PL), as compared with solely the pelvic lymphadenectomy. Materials and Methods: A retrospective study of patient outcomes was conducted of ovarian cancer patients who underwent optimal debulking surgery, concurrent with either PA + PL or PL alone, between 2000 and 2009 at our Osaka General Medical Center. Results: One hundred twenty-one patients with ovarian cancer underwent surgery. Forty-four patients (36%) underwent optimal debulking surgery (all residual disease was 1 cm) concurrent with lymphadenectomy. Seventeen patients underwent PA + PL (PA group), and 27 patients underwent PL alone (PL group). There were no significant differences in terms of overall survival (OS; hazard ratio [HR] = 0.49; 95% CI, 0.13 to 1.82; p = 0.29) and progression-free survival (PFS; HR = 0.62; 95% CI, 0.19 to 2.00; p = 0.40) between the PA group and the PL group. Both OS and PFS also failed to show significant differences, even when comparing them among 26 cases of FIGO stage I cases. Conclusions: Our data failed to show any prognostic improvement for ovarian cancer by adding para-aortic lymphadenectomy to the standard pelvic lymphadenectomy regimen.